NLRP3 Inhibitor Discovery Screen: Food-Derived Compounds for Engineered Microbe Production¶

Executive Summary¶

This screen evaluates food-derived NLRP3 inflammasome inhibitors producible by engineered S. cerevisiae or A. oryzae, ranked by:

TCM lineage note (2026-05-05): Several compounds in this screen have explicit TCM materia medica lineage — oridonin (Rabdosia rubescens / Dong Ling Cao 冬凌草), EGCG (green tea / Lu Cha 绿茶), resveratrol (Polygonum cuspidatum / Hu Zhang 虎杖), curcumin (turmeric / Jiang Huang 姜黄), berberine (Coptis chinensis / Huang Lian 黄连). The methodology for applying modern scientific rigor to these compounds — including chokepoint mapping, ChEMBL cross-check, and bioavailability-honest framing — is formalized in tcm-modern-rigor-intersection.md. (source: tcm-modern-rigor-intersection.md) 1. NLRP3 inhibition evidence strength (clinical > animal > in vitro > mechanistic) 2. Microbial production feasibility (established biosynthetic pathways, expression titers, known host organisms) 3. Food-safety status (GRAS or traditional use in fermented foods)

Benchmark compounds: - MCC950 — IC50 ~7.5 nM (crystalline NLRP3 inhibitor, not food-derived) - Oridonin — Covalent Cys279 binder (plant diterpenoid, not easily synthesized) - Tranilast — Non-selective mast cell stabilizer - OLT1177 (dapansutrile) — Phase 2a gout trial success, direct NLRP3 ATPase inhibitor

Species-gap caveat (methodological standard, 2026-04-23): Rodent cellular IC50 values for NLRP3 inhibitors routinely diverge from human cellular IC50 by up to 3 orders of magnitude. Example: dapansutrile IC50 = 1 nM in mouse J774A.1 cells vs. 1,000 nM (1 μM) in human MDM cells under LPS+nigericin stimulation (ChEMBL v34). Every rodent-derived IC50 in this document should be read with that translation uncertainty in mind. When evaluating new compounds, prefer human-cell (THP-1, PBMC, human MDM) data over rodent cellular assays. (source: chembl-cross-check.md)

Candidate Compounds Evaluated¶

Tier 1: Strong NLRP3 Evidence + Established Microbial Production¶

1. Quercetin (3,3',4',5,7-pentahydroxyflavone)¶

NLRP3 Mechanism: (In vitro & animal model) - Suppresses NLRP3 inflammasome activation and ASC oligomerization - Inhibits NF-κB and NLRP3 expression via SIRT1 pathway - Mechanism: mitochondrial protection, upstream IL-1β suppression

Evidence Level: - In vitro: Quercetin (IC50 ~11.0 μM) blocks NLRP3 in macrophage lysates - Animal (MSU-induced gout): 200–400 mg/kg quercetin in rats reduced joint edema, IL-1β, TNF-α, COX-2, and PGE2 within 24 h (Clinical trial evidence: NOT published; mechanistic hypothesis only) - Human gout: Quercetin prevents hyperuricemia-associated gouty arthritis via NLRP3/NF-κB inactivation (recent 2025 evidence in literature, but not RCT data)

Production Feasibility: - S. cerevisiae: Engineered strains produce kaempferol (26.57 ± 2.66 mg/L) and quercetin (20.38 ± 2.57 mg/L) from glucose via heterologous expression of plant PAL, CHS, CHI, and F3H genes - Pathway requirement: Phenylpropanoid pathway (6–8 heterologous plant genes from Arabidopsis, Petroselinum) - Feasibility: HIGH — established pathway reconstruction in GRAS yeast; titers sufficient for oral dosing (assuming 10 mg per dose)

Food Safety: - GRAS status: Quercetin-rich foods (onions, apples, berries) widely consumed - Solubility: Low (poor bioavailability as aglycone) - Dosing in fermented products: 50–100 mg/mL achievable via engineered yeast

Advantages: - Multiple synergistic mechanisms (antioxidant + direct NLRP3 block) - Co-production feasible with uricase construct in same yeast

Limitations: - IC50 (11 μM) >> benchmark MCC950 (7.5 nM); ~1500× weaker - No human gout RCT - Bioavailability severely limited by poor water solubility

Ranking Rationale: Tier 1 due to gout-specific animal evidence and mature biosynthetic production platform. Weakness is IC50 potency vs. benchmark.

2. Ursolic Acid (3β-hydroxy-urs-12-en-28-oic acid)¶

NLRP3 Mechanism: (In vitro & animal) - Pentacyclic triterpene; suppresses NF-κB, AP-1, NF-AT transcription factors - Blocks NLRP3 inflammasome assembly and caspase-1 activation - Inhibits pro-IL-1β expression upstream

Evidence Level: - In vitro: Ursolic acid suppresses NLRP3 inflammasome in multiple cell types (macrophages, endothelial cells) - Animal (Kawasaki disease, vascular injury model): Ursolic acid inhibited NLRP3 inflammasome activation and reduced vascular smooth muscle injury - Gout-specific: NOT directly tested; evidence inferred from osteoarthritis models showing NLRP3 suppression

Production Feasibility: - S. cerevisiae: Recently engineered to produce ursolic acid and oleanolic acid via combinatorial metabolic engineering - Recent 2024 achievement: 1083.62 mg/L in shake flask; 8.59 g/L in fed-batch 5L bioreactor (highest microbial titer reported) - Pathway: Mevalonate (MVA) pathway optimization + heterologous OSC (oxidosqualene cyclase), CYP (cytochrome P450), CPR (cytochrome P450 reductase) from plants (Catharanthus roseus, Glycyrrhiza) - Host: GRAS S. cerevisiae (food-grade)

Food Safety: - GRAS status: Ursolic acid present in apples, rosemary, oregano, thyme - Traditional use: Chinese medicine (Radix Salviae Divinorum) - Solubility: Poor in water; typically requires lipid formulation - Dosing: 100–200 mg/day in human trials

Advantages: - HIGHEST microbial production titer (8.59 g/L bioreactor) — exceeds any polyphenol production - Structurally stable triterpene; resistant to gastrointestinal degradation - Can be formulated with lipid excipients in fermented beverage or solid dosage - Multiple mechanistic targets beyond NLRP3 (anti-inflammatory, anti-oxidant)

Limitations: - IC50 not quantified vs. MCC950 or oridonin (appears to be in μM range from structure activity) - No gout-specific animal evidence (extrapolation from OA models) - Requires two additional metabolic engineering modules (MVA optimization + triterpene synthase pathway)

Ranking Rationale: Tier 1 due to exceptional production titer (8.59 g/L), GRAS status, and structural stability. NLRP3 mechanism confirmed but not gout-tested.

3. Taurine (2-aminoethanesulfonic acid)¶

NLRP3 Mechanism: (Animal & mechanistic) - Amino acid; upstream inhibitor of NLRP3 inflammasome assembly - Mechanism: prevents K+ efflux → blocks inflammasome speck formation - Restores intracellular taurine that is depleted during NLRP3 activation - Also reduces pyroptosis (GSDMD-mediated cell death)

Evidence Level: - In vitro: Taurine restoration in cultured macrophages reverses K+ efflux-induced NLRP3 speck assembly - Animal (sepsis, cardiac injury, hemorrhage): Taurine infusion protected mice against sepsis mortality, reduced myocardial IL-1β at levels comparable to CP-456,773 (NLRP3 inhibitor) and pyrrolidine dithiocarbamate (NF-κB inhibitor); reduces NLRP3, caspase-1, GSDMD - Gout-specific: NOT tested; mechanistic inference only

Production Feasibility: - S. cerevisiae or A. oryzae: Taurine synthesis pathway is natural to mammals; bacteria also produce it - Heterologous pathway: Cysteine → cysteic acid → taurine (requires cysteinyl-CoA synthetase, cysteate sulfinyltransferase) - Engineering status: Feasible; taurine biosynthesis genes from E. coli or Corynebacterium have been cloned - Titers: Not extensively published for engineered yeast, but expected to be high (taurine is small, non-toxic amino acid)

Food Safety: - GRAS status: Essential amino acid; widely consumed (meat, seafood, energy drinks, dietary supplements) - Safe up to 3 g/day in humans - Naturally produced by A. oryzae during koji fermentation (small amounts)

Advantages: - Oral bioavailability: Excellent (amino acid; actively transported) - Safety profile: Decades of clinical use; no toxic interaction profiles at physiological levels - Mechanistic clarity: Well-characterized K+ efflux block upstream of ASC oligomerization - Synergy potential: May enhance uricase efficacy by suppressing IL-1β-driven renal urate reabsorption

Limitations: - Weak potency vs. benchmark: Direct inhibitor IC50 not applicable (upstream NLRP3 activator block, not direct enzyme inhibition) - No gout clinical evidence: Only mechanistic extrapolation from sepsis and cardiac models - Biosynthetic pathway complexity: Requires 2–3 heterologous enzymes; lower titers than quercetin or ursolic acid expected

Ranking Rationale: Tier 1 candidate for synergy with other NLRP3 inhibitors, not as standalone agent. Excellent bioavailability and safety make it ideal for co-production with polyphenols. Evidence strong in sepsis and cardiac contexts but not gout-specific.

3a. Lactoferrin (bovine rbLf / porcine rpLF) — NEW Tier 1 CP5 Entry¶

NLRP3 Mechanism: (In vitro & animal; CP5 — IL-1β / IL-18 output suppression) - Glycoprotein (~80 kDa) that suppresses the NLRP3 / caspase-1 / GSDMD axis → reduces IL-1β and IL-18 output - Multi-tissue anti-inflammatory evidence (renal, intestinal, macrophage) - Talactoferrin (recombinant human lactoferrin, ChEMBL2108651) reached Phase 3 oncology — establishes oral bioavailability + safety at multi-g/day doses

Evidence Level: - Animal (murine nephrotoxicity, PMID 37926296): 300 mg/kg/day lactoferrin suppressed renal NLRP3 / caspase-1 / GSDMD and reduced IL-1β/IL-18. Back-translates to ~3 g/day human — achievable at demonstrated fermentation scale. (Animal Model.) - Animal (radiation enteritis): protective against GI-barrier inflammation; GSDMD-axis mechanism. - In vitro: macrophages + IEC-6 intestinal epithelial cells — NLRP3/caspase-1/GSDMD axis suppression confirmed. - Clinical (Phase 3): Talactoferrin (ChEMBL2108651) — oral bioavailability + safety established at multi-g/day doses. - Gout-specific: Not yet directly tested in MSU model; CP5 mechanism (IL-1β/IL-18 output block) is the gout-relevant target class.

Production Feasibility: - Pichia pastoris (KM71-H, AOX1 promoter): 3.5 g/L bovine rbLf (Iglesias-Figueroa 2016, Int J Mol Sci, PMID 27294912) — highest demonstrated titer - Porcine rpLF: 2.8 g/L (Yen 2024, PMID 38339093) - A. oryzae (koji): Not yet attempted — potential future module for the Open Enzyme koji platform, would fit the GRAS food-organism vision - Native source: Bovine colostrum (commercial lactoferrin capsules available at ~100–300 mg/day)

Food Safety: - GRAS: Bovine lactoferrin (colostrum, milk); decades of dietary use as infant formula additive - Dose precedent: 100–300 mg/day oral in commercial capsules; up to gram-scale in Phase 3 talactoferrin trials

Strategic Position: - The only CP5 candidate that is fermentable at scale, food-grade, and has direct NLRP3/IL-1β evidence. - Fills the Open Enzyme CP5 gap that canakinumab currently occupies at ~$300K/year. - Orthogonal mechanism to polyphenol NLRP3 pathway modulators (CP1) and direct NLRP3 binders (CP2). - P. pastoris 3.5 g/L titer exceeds all polyphenol candidates; engineering path is well-characterized.

Ranking Rationale: Tier 1 CP5 entry based on demonstrated 3.5 g/L fermentation, Phase 3 clinical precedent (talactoferrin), direct NLRP3/caspase-1/GSDMD-axis evidence at CP5, and GRAS food-grade status. Gap: direct MSU-gout validation not yet in the literature — recommend as a priority experimental screen.

Tier 2: Moderate NLRP3 Evidence + Feasible Microbial Production¶

4. Resveratrol (3,5,4'-trihydroxystilbene)¶

NLRP3 Mechanism: (In vitro & animal) - Stilbenoid polyphenol; non-covalent NLRP3 binding - Primary mechanisms: mitochondrial integrity preservation, SIRT1-dependent autophagy, reduction of ROS-driven NLRP3 priming - Does NOT directly bind Cys279 (unlike oridonin); mechanism is functional modulation

Evidence Level: - In vitro: Resveratrol (0.1–25 μM) suppresses NLRP3 inflammasome in microglia and macrophages via SIRT1/AMPK pathway - Animal (ischemia-reperfusion, arthritis, Toxoplasma infection): Resveratrol reduced NLRP3 activation and IL-1β in CIA (collagen-induced arthritis) mice, Toxoplasma-infected lungs, cardiac IR injury - Gout-specific: Weak indirect evidence via rheumatoid arthritis models

Production Feasibility: - S. cerevisiae: Engineered strains produce resveratrol from glucose - 2020 benchmark: 800 mg/L resveratrol in fed-batch fermentation (highest yeast titer reported for polyphenols) - Pathway: PAL (phenylalanine ammonia-lyase) + STS (stilbene synthase) from Vitis vinifera or Arachis hypogaea - Feasibility: HIGH — mature platform; titers exceed quercetin

Food Safety: - GRAS: Resveratrol in grapes, wine, berries - Solubility: Poor (requires formulation with lipids or cyclodextrin) - Safety: Well-tolerated up to 2.5 g/day in humans

Advantages: - Highest documented polyphenol production titer (800 mg/L) - Extensive human safety database (wine polyphenol; dietary supplement for decades) - Multiple mechanisms (autophagy, SIRT1, mitochondrial homeostasis) suggest broad NLRP3 suppression

Limitations: - IC50 vs. NLRP3 not quantified; estimates in μM range (>>benchmark MCC950) - No direct covalent binding to NLRP3 Cys279; purely functional modulation - No gout-specific animal evidence - Bioavailability severely limited by poor water solubility (~3 mg/L)

Ranking Rationale: Tier 2 due to high production titers and safety profile, but weaker NLRP3 specificity vs. quercetin or ursolic acid. Not primary candidate but excellent synergy agent.

5. Carnosine (β-alanyl-histidine)¶

NLRP3 Mechanism: (In vitro & animal) - Dipeptide; suppresses NLRP3 inflammasome-driven pyroptosis - Mechanism: Reduces ROS, suppresses p65 (NF-κB), inhibits JNK phosphorylation; downstream NLRP3, caspase-1, URAT1, GLUT9 suppression - Anti-inflammatory via SIRT1 and HDAC inhibition

Evidence Level: - In vitro: Carnosine (100–500 μM) attenuated LPS-induced NLRP3 activation and pyroptosis in aged rat neurons and HK-2 (kidney) cells - Animal (diabetes, aging, LPS-induced inflammation): Carnosine in STZ-induced diabetic mice reduced renal NLRP3, ASC, pro-IL-1β, mature IL-1β, IL-18; protected against kidney injury - Gout-specific: YES — direct evidence: Carnosine reduces serum uric acid in hyperuricemia rats via restoring hepatorenal function and enhancing uric acid excretion while inhibiting inflammation

Production Feasibility: - S. cerevisiae: Carnosine synthesis pathway is bacterial (from Lactobacillus, Carnobacterium) - Enzymatic route: β-alanine + L-histidine → carnosine (via carnosine synthase) - Engineering challenge: β-alanine is not naturally abundant in yeast; requires upstream synthesis from aspartate or serine - Status: NOT extensively published for engineered yeast; feasible but more complex than single-enzyme transglycosidases - Estimated titers: Moderate (~100–500 mg/L) based on analogous dipeptide engineering

Food Safety: - GRAS: Carnosine present in muscle meats, poultry - Safe: Typical dietary intake ~50–150 mg/day; clinical trials use up to 1–2 g/day - Non-toxic at high doses

Advantages: - DIRECT GOUT EVIDENCE: Only candidate with published hyperuricemia rat data showing reduced serum uric acid AND NLRP3 inhibition - Excellent oral bioavailability (dipeptide; absorbed intact via peptide transporters) - Multi-target mechanism (ROS, p-p65, p-JNK, NLRP3, URAT1, GLUT9) suggests combinatorial benefit - Synergistic with uricase: reduces renal uric acid reabsorption while enzymatic activity degrades luminal urate

Limitations: - Production complexity: Requires 2–3 enzymes + upstream β-alanine synthesis; titers likely lower than quercetin or ursolic acid - Not widely engineered in yeast (publication gap) - Mechanism: NF-κB-dependent suppression, not direct NLRP3 binding (less potent than oridonin-like compounds)

Ranking Rationale: Tier 2; PROMOTED due to direct gout evidence (only candidate with hyperuricemia rat data linking uric acid reduction to NLRP3 inhibition). Production complexity and lower potency prevent Tier 1 ranking.

Tier 3: Polyphenols with Strong NLRP3 Evidence but Variable Production Feasibility¶

6. EGCG (Epigallocatechin-3-gallate)¶

NLRP3 Mechanism: (In vitro & animal; widest-spectrum natural compound in the stack — 4 of 7 chokepoints) - CP1 (NF-κB priming): IKK inhibition → blocks NF-κB transcriptional priming of NLRP3 / pro-IL-1β - CP1a (TNFSF14 / LIGHT direct suppression): Hosokawa 2010 (PMID 20461739) — the only stack compound with direct TNFSF14 data. Gout-relevant since TNFSF14 is an emerging gout-specific priming amplifier (see tnfsf14-gout-target.md). - CP4 (caspase-1 suppression): indirect via 20S proteasome inhibition, IC50 = 86 nM (ChEMBL). Sub-100 nM proteasome potency is a hepatotoxicity dose-ceiling flag at high-dose intense-use protocols. - CP5a (IL-1β receptor-downstream suppression): reduces IL-1β-induced signaling in target cells (chondrocytes, synoviocytes) - Green tea catechin; also suppresses ROS-driven NLRP3 activation and K⁺-efflux priming as adjunct mechanisms - Summary framing: EGCG is the widest-spectrum natural compound in the current Open Enzyme stack, hitting four of seven chokepoints (CP1, CP1a, CP4, CP5a). Its 20S proteasome sub-100 nM activity is a hepatotoxicity flag at high dose — safety dose-ceiling for intense use protocols.

Evidence Level: - In vitro: EGCG (10–50 μM) attenuated α-hemolysin-induced NLRP3 inflammasome and reduced caspase-1, IL-1β, IL-18; direct binding to Hla (Kd = 1.71 × 10⁻⁴ M) - Animal (T2D, bacterial infection models): EGCG improved glucose tolerance and prevented NLRP3-inflammasome-dependent inflammation in high-fat-diet mice; reduced bacterial lipopolysaccharide-induced NLRP3 activation - Gout-specific (re-audit 2026-04-23, PROMOTED): Direct MSU mouse gout evidence — Lee 2019 Molecules (PMID 31174271): EGCG blocked MSU-induced caspase-1(p10) and IL-1β in primary mouse macrophages; oral EGCG alleviated MSU-injected mouse foot inflammation via NLRP3 suppression; mechanism = mtDNA synthesis block + ROS reduction. Hyperuricemic mouse serum-UA lowering — Yu 2024 Food Funct (PMID 38757391). The prior "no gout-specific evidence" framing was keyword-gated and missed these. (Animal Model; source: nlrp3-inhibitor-screen.md 2026-04-23 re-audit)

Production Feasibility: - S. cerevisiae: EGCG synthesis requires 8–10 heterologous plant genes (PAL, C4H, 4CL, CHS, CHI, F3H, F3'H, FLS, plus GT for galloylation) - Estimated titers: 10–50 mg/L (lower than kaempferol or quercetin due to galloylation complexity) - Feasibility: MODERATE — pathway complexity is highest among polyphenols; multiple post-translational modifications

Food Safety: - GRAS: Green tea extract (40% EGCG) in dietary supplements - Safe: Clinical trials use 400–800 mg/day EGCG - Bioavailability: ~20–30% oral absorption (undergoes gut metabolism)

Advantages: - Multiple ROS reduction mechanisms; strong antioxidant activity - Established clinical use in dietary supplements - Synergistic with TLR4/NF-κB suppression (upstream priming block)

Limitations: - Production titers likely 10–50 mg/L (lowest among evaluated polyphenols) - Pathway complexity (8–10 heterologous genes + galloylation) - No gout-specific evidence - Bioavailability limited (~20–30%); undergoes extensive gut metabolism

Ranking Rationale: Promoted to Tier 2 (from Tier 3) following 2026-04-23 literature re-audit: direct MSU mouse gout evidence (Lee 2019 PMID 31174271) and hyperuricemic mouse serum-UA lowering (Yu 2024 PMID 38757391) contradict the prior "no gout-specific evidence" framing. Engineered-production complexity (8–10 gene pathway, 10–50 mg/L titers) remains the limiting factor for a Tier 1 ranking, not evidence. Supplement-tier use (400–800 mg/day green tea extract) is a shorter path than engineered yeast production.

7. Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)hpta-1,6-diene-3,5-dione)¶

NLRP3 Mechanism: (In vitro & animal, gout-specific) - Curcuminoid phenolic; suppresses K+ efflux and mitochondrial dysfunction - Blocks ASC oligomerization and speckle formation downstream - Also inhibits ROS/NEK7-NLRP3 complex assembly - Suppresses NF-κB signaling (upstream priming)

Evidence Level: - In vitro: Curcumin (10–50 μM) blocked MSU-induced NLRP3 inflammasome assembly and IL-1β secretion in macrophages - Animal (MSU gout model): Curcumin (~100 mg/kg) reduced joint swelling, inflammatory cell infiltration, and NLRP3 inflammasome activity in mouse gout arthritis; suppressed NF-κB pathway - Gout-specific: YES — demonstrated efficacy in MSU-induced acute gout arthritis model

Production Feasibility: - S. cerevisiae: Curcumin synthesis requires phenylpropanoid pathway + phenolic coupling (PAL, CHS, CPR/CYP for 4-hydroxylation, or acetyl-CoA + phenol oxidative coupling) - Feasibility: MODERATE — pathway known but complex (6–8 heterologous genes); main challenge is oxidative coupling chemistry - Estimated titers: 50–200 mg/L (comparable to EGCG; not extensively published for engineered yeast)

Food Safety: - GRAS: Turmeric (contains 2–8% curcumin) - Safe: Clinical trials up to 8 g/day; low toxicity - Critical limitation: Poor bioavailability (~5% oral absorption; extensive first-pass metabolism) - Requires lipid formulation (piperine co-supplement, nanoparticles, liposomes) for effective oral dosing

Advantages: - Direct gout animal evidence: Demonstrated efficacy in MSU-induced arthritis - Multiple mechanistic targets (K+ efflux, ASC, ROS, NF-κB, NEK7) - Well-characterized NLRP3 suppression mechanism - Therapeutic efficacy in murine gout arthritis model

Limitations: - Severe bioavailability crisis: Only ~5% oral absorption; requires sophisticated formulation - Intensive metabolism by gut microbiota and liver (UDP-glucuronosyltransferase, sulfotransferase) - Would require co-engineering of bioavailability enhancers (piperine, lipid formulation) if used - High engineering complexity (~8 genes for phenylpropanoid synthesis + oxidative coupling)

Ranking Rationale: Tier 3 due to exceptional gout evidence but crippling bioavailability limitations. Requires co-formulation strategy (e.g., piperine from black pepper fermentation, liposome delivery) to be clinically viable.

Tier 4: Terpenoids with NLRP3 Mechanism but Limited Production Evidence¶

8. β-Caryophyllene (4-isopropyl-1-methyl-1-cyclohexene + 2-methyl-6-methylene-2,7-octadiene)¶

NLRP3 Mechanism: (In vitro & animal) - Sesquiterpene; CB2 receptor agonist; NLRP3 inhibition via anti-inflammatory and antioxidant pathways - Decreases NLRP3, caspase-1, and MDA (malondialdehyde) expression - Reduces neuroinflammation in Parkinson's model

Evidence Level: - In vitro: β-caryophyllene suppresses NLRP3 expression and inflammasome assembly in neuroinflammation models - Animal (hemiparkinsonism): β-caryophyllene reduced neuroinflammation and protected dopaminergic neurons via NLRP3 inflammasome inhibition - Animal (MSU-induced gouty arthritis in rats): 100, 200, 400 mg/kg reduced ankle swelling, serum IL-1β/IL-6/TNF-α, and synovial NLRP3/caspase-1/ASC/TLR4/NF-κB expression. Computational docking shows NLRP3 binding (CDOCKER energy 31.92 kcal/mol). Direct gout model evidence — this entry needs re-ranking (see cannabinoids-terpenes.md). Front Pharmacol 2021;12:651305. PMID: 33967792. - Gout-specific: YES (MSU crystal model, animal)

Production Feasibility: - S. cerevisiae: β-Caryophyllene is a volatile sesquiterpene; engineered yeast can produce sesquiterpenes via mevalonate + sesquiterpene synthase (STS) heterologous expression - Status: Published for engineered S. cerevisiae but titers are low (~10–50 mg/L in flask culture) - Challenge: Volatility; product loss during fermentation; requires advanced bioreactor design (in situ product recovery)

Food Safety: - GRAS: β-Caryophyllene in black pepper, cloves, hops, cannabis - Safe: Food additive status in multiple jurisdictions - Volatile; bioavailability as aerosolized/vaporized form > oral

Advantages: - Well-characterized NLRP3 mechanism via CB2 - Natural GRAS food component - Potential for inhalational delivery (lung inflammation)

Limitations: - Very low production titers (~10–50 mg/L) vs. polyphenols (~800 mg/L for resveratrol) - Volatile; product loss in fermentation - No gout-specific evidence - Sesquiterpene synthase expression in yeast is less mature than monoterpene (limonene) or triterpene (ursolic acid) pathways

Ranking Rationale: Tier 4 for microbial production (low titers, volatility). Re-ranked to Tier 2–3 for supplement stack given direct MSU gout animal model data (2021). For supplementation from black pepper/clove extracts, beta-caryophyllene is the only terpene or cannabinoid with published gout-model evidence. See cannabinoids-terpenes.md for full analysis.

9. Limonene (4-isopropenyl-1-methylcyclohexene, d-limonene)¶

NLRP3 Mechanism: (In vitro & animal) - Monoterpene; suppresses NF-κB and NLRP3 inflammasome components via NRF2 induction - Reduces TLR4 signaling (upstream NLRP3 priming block) - Antioxidant via NRF2-dependent glutathione synthesis

Evidence Level: - In vitro: Linalool (related monoterpene) suppresses TLR4, NF-κB, NLRP3, ASC, caspase-1 expression - Animal: Limonene and linalool reduce inflammation via NRF2 pathway in various models - Gout-specific (re-audit 2026-04-23, PROMOTED): Direct rat PO+MSU dual model — Venkatesan 2025 Nutrients (PMID 41515190): 50 mg/kg limonene reduced paw thickness, serum UA, IL-1β/TNF/IL-6, improved antioxidant status; authors invoke NLRP3-IL-1β suppression as the mechanistic frame. (Animal Model; source: nlrp3-inhibitor-screen.md 2026-04-23 re-audit)

Production Feasibility: - S. cerevisiae: Limonene is a volatile monoterpene; engineered yeast via mevalonate + limonene synthase heterologous expression - Status: Published but titers are very low (~5–20 mg/L); volatility is major issue - Bioavailability: Poor for oral (volatile; absorbed mainly via inhalation/vapor)

Food Safety: - GRAS: Limonene in citrus peels, essential oils - Safe: Food flavoring; typical intake <10 mg/day from food

Advantages: - NLRP3 mechanism clear (NRF2/TLR4 block) - Natural GRAS compound

Limitations: - Extremely low production titers (<20 mg/L) - Volatility makes fermentation recovery impractical - No oral bioavailability (requires vaporization) - No gout evidence - Not suitable for oral urate-lowering formulation

Ranking Rationale: Supplement use promoted to Tier 3 (direct rat PO+MSU gout model per Venkatesan 2025 PMID 41515190). Engineered-production path stays Tier 4 due to volatility (<20 mg/L fermentation titers, poor oral bioavailability without inhalation/vaporization). Two separate tiers for two separate strategies: buy the d-limonene capsule; do not engineer the yeast.

10. Sulforaphane (1-isothiocyanato-4-(methylsulfinyl)butane) — PROMOTED 2026-04-23¶

NLRP3 Mechanism: (In vitro & animal, hyperuricemia) - Isothiocyanate; potent Nrf2 activator via Keap1-Cys151 covalent modification - Sub-μM Nrf2 activation: EC50 = 580 nM (J Med Chem 2019) — crosses into the potency range of synthetic NLRP3 modulators - Nrf2 cross-talk with NF-κB: Nrf2 competes with NF-κB for CBP/p300 transcriptional co-activator, suppressing NLRP3 and pro-IL-1β transcription - PYCARD (ASC) promoter methylation effects inferred from broader Nrf2 epigenetic program

Evidence Level: - In vitro: Sub-μM Nrf2 activation (EC50 580 nM, J Med Chem 2019) - Animal (hyperuricemia, re-audit 2026-04-23, PROMOTED): Wang 2022 J Adv Res (PMID 36371056): hyperuricemic rat model — sulforaphane decreased urate synthesis + increased renal urate excretion + Nrf2-mediated epigenetic modification of urate-handling genes. Dual mechanism (synthesis block + excretion enhancement) bridges the uric-acid and inflammation axes. (Animal Model; source: nlrp3-inhibitor-screen.md 2026-04-23 re-audit) - Gout-specific (direct MSU, 2026-05-05 audit, ADDED): Yang 2018 Rheumatology (Oxford) (PMID 29340626): oral sulforaphane attenuated MSU-crystal-induced foot-pad swelling and neutrophil recruitment in mice; air-pouch gout model confirmed in vivo NLRP3 suppression; in primary mouse macrophages SFN suppressed NLRP3 inflammasome activation by MSU, ATP, and nigericin (but not poly(dA:dT)) independent of ROS, suggesting direct action on the NLRP3 complex. (Animal Model; oral administration; source: 2026-05-05 audit) - Mechanistic (Nrf2-independent inflammasome inhibition, 2026-05-05 audit, ADDED): Greaney 2015 J Leukoc Biol (PMID 26269198): sulforaphane inhibits NLRP1, NLRP3, NAIP5/NLRC4, and AIM2 inflammasomes in macrophages independent of Nrf2 / antioxidant response element pathway — distinct from the classical Nrf2 → NF-κB cross-talk mechanism. Confirmed in vivo via acute gout peritonitis model (cell recruitment + IL-1β secretion ↓). Adds a direct caspase-1 / inflammasome-assembly mechanism on top of the Nrf2 → ABCG2 / NF-κB axis. (In Vitro + Animal Model; source: 2026-05-05 audit)

Production Feasibility: - S. cerevisiae / A. oryzae: No published engineered microbial production. Requires glucosinolate (glucoraphanin) pathway (6+ heterologous plant genes from Brassica) + myrosinase activation - Food-industry path: Freeze-dried broccoli sprouts with active myrosinase (10–20 mg sulforaphane/serving) — shorter than engineered production - Engineering complexity: HIGH (pathway never reconstructed in yeast); Tier 4 for engineered production

Food Safety: - GRAS: Broccoli sprouts, mustard, watercress - Clinical trials: up to 150 μmol/day oral sulforaphane well-tolerated

Advantages: - Sub-μM Nrf2 potency (580 nM EC50) — rare among food-derived compounds - Hyperuricemic rat validation (Wang 2022) bridges urate + inflammation - Food-industry supply chain already exists (broccoli sprout capsules) - Mechanistically additive with quercetin (different target class)

Limitations: - No engineered microbial production path - Gout-specific MSU model not yet tested (hyperuricemia extrapolation only) - Isothiocyanate reactivity: off-target thiol covalent modification at high doses

Ranking Rationale: Promoted to Tier 2 for supplement use (Yang 2018 direct MSU foot-pad acute gout + Wang 2022 hyperuricemic rat + Greaney 2015 Nrf2-independent inflammasome mechanism + sub-μM Nrf2 EC50). The 2026-05-05 audit upgraded sulforaphane from Tier 2–3 to Tier 2 — three independent in vivo gout-relevant readouts now exist. Engineered-production path stays Tier 4 — glucosinolate pathway has never been reconstructed in yeast and the food-industry broccoli-sprout route is shorter.

11. Theaflavins (TF1, TF2A, TF2B, TF3) — ADDED 2026-05-05¶

NLRP3 Mechanism: (In vitro & animal, MSU peritonitis) - Theaflavins are the dominant red-orange polyphenols of black tea / oolong / pu'er, formed by polyphenol-oxidase oxidation of EGCG and ECG during fermentation - Mechanism is distinct from EGCG: theaflavins disrupt NLRP3-NEK7 interaction downstream of mitochondrial ROS suppression, blocking inflammasome assembly (CP2/CP3) rather than EGCG's proteasome-mediated CP1a route - Suppress ASC speck formation and oligomerization → blocked caspase-1 p10 cleavage, GSDMD-NT pyroptosis, mature IL-1β release - TF3 (theaflavin-3,3'-digallate) is the most potent fraction across in vitro assays - Secondary CP1a coverage: Hosokawa 2010 (PMID 20461739) — TF3 + EGCG + ECG suppress TNFSF14-induced IL-6 and downregulate HVEM receptor on target cells

Renal urate handling (unique to theaflavins, not shared with EGCG): - ↓ URAT1, ↓ GLUT9 (apical and basolateral reabsorption block) - ↑ OAT1, ↑ OCTN1, ↑ OAT2, ↑ Oct½ (proximal-tubule secretion) - This is the only multi-transporter renal urate handling profile in the wider OE supplement stack besides carnosine (which faces serum carnosinase clearance ceiling)

Evidence Level: - In vitro (MSU NLRP3 assembly, 2026-05-05 audit, ADDED): Chen 2023 Acta Pharmacol Sin (PMID 37221235): 50–200 μM theaflavin dose-dependently inhibited NLRP3 inflammasome activation in LPS-primed macrophages stimulated with ATP, nigericin, or MSU crystals. (In Vitro) - Animal (oral, MSU peritonitis): Same Chen 2023 paper — oral theaflavin significantly attenuated MSU-induced mouse peritonitis (acute-gout-flare proxy model); also rescued bacterial sepsis survival via the same NLRP3-NEK7 mechanism. (Animal Model) - Mechanism review: Chen 2023 Phytomedicine (PMID 36990009): comprehensive anti-gout mechanism review covering URAT1/GLUT9 downregulation + OAT1/OCTN1/OAT2 upregulation + network-pharmacology prediction (ABCB1, MAPK14, TERT, STAT1, MMP2/14, BCL2 as anti-gout targets).

Production Feasibility: - S. cerevisiae / A. oryzae: No engineered route. Theaflavin biosynthesis requires plant polyphenol oxidase + EGCG and ECG substrates — full pathway has never been reconstructed in yeast or bacteria, and substrate cost would dominate. Tier 4 for engineered production. - Food-industry path: Black tea (1–2% theaflavins by dry weight), oolong, pu'er; concentrated supplement extracts standardized to 30–80% TF content. Mature commercial supply chain.

Food Safety: - GRAS: Black tea, all common tea types - Cardiovascular and lipid trials: 700–2,500 mg/day theaflavin-enriched extract for 12+ weeks well-tolerated - TF3 standardized extracts in commercial OTC supplements

Advantages: - Mechanism-orthogonal to EGCG at the NLRP3 step (assembly disruption vs. proteasome) — additive when stacked - Unique URAT1 downregulation in the OE stack (without carnosine's carnosinase ceiling) - Direct MSU peritonitis Animal Model (oral) - Mature commercial supply (theaflavin-enriched extracts)

Limitations: - Poor oral bioavailability (~0.1–1%); same formulation challenge as EGCG - In vitro effective concentrations (50–200 μM) are 100× higher than achievable plasma exposures from oral dosing — in vivo MSU peritonitis effect may operate via a different mechanism at lower concentrations - No human gout RCT; dose extrapolated from cardiovascular trials - No engineered microbial production route

Ranking Rationale: Tier 2 supplement candidate (direct MSU peritonitis Animal Model + multi-mechanism URAT1/GLUT9/OAT modulation + secondary TNFSF14/HVEM coverage). The mechanism breadth is comparable to EGCG; the unique URAT1 angle pulls in a chokepoint EGCG doesn't reach. Engineered-production path: Tier 4 — no microbial route. See theaflavins.md for the full dossier.

Meta-Finding: Keyword-Gating Failure in Prior Tier-4 Classification¶

Methodological correction (2026-04-23 re-audit): The original Tier-4 classifications for EGCG, limonene, and sulforaphane were keyword-gated on the literal strings "MSU" / "gout" in PubMed abstracts, which missed direct MSU-gout animal models (EGCG, limonene) and hyperuricemia rat models (sulforaphane) that frame the inflammation via "uric acid" or "hyperuricemia" without using the word "gout."

New methodological standard (per scripts/sweep-prompt.md update): Pass 2 sweeps should explicitly check: 1. MSU-crystal animal models (any species, foot/paw/peritonitis/joint) 2. Hyperuricemia animal models (uric-acid lowering in rats/mice) 3. Human-cell NLRP3 assays (THP-1, PBMC, MDM) separate from mouse-cell data 4. Nrf2 / NF-κB pathway activity at sub-μM potency (not just direct NLRP3)

for every compound, not just those with "gout" in the title. Applied retroactively: EGCG → Tier 2; limonene → Tier 3 supplement / Tier 4 production; sulforaphane → Tier 2–3 supplement / Tier 4 production.

2026-05-05 follow-up audit (PubMed full-text + bioRxiv): Sulforaphane upgraded from Tier 2–3 to Tier 2 with two additional citations (Yang 2018 PMID 29340626 direct MSU foot-pad acute gout; Greaney 2015 PMID 26269198 Nrf2-independent inflammasome inhibition). Theaflavins added as a new Tier 2 entry (Chen 2023 PMID 37221235 direct MSU peritonitis Animal Model + Chen 2023 PMID 36990009 multi-transporter URAT1/GLUT9/OAT review). α-Pinene confirmed: no direct MSU/gout animal-model data exists; Tier 4 ranking stands.

Native A. oryzae Metabolites: Screening for Inherent NLRP3 Activity¶

Koji (Aspergillus oryzae) produces multiple bioactive metabolites:

Kojic acid (5-hydroxy-2-(hydroxymethyl)-4-pyrone)
Antioxidant; melanin synthesis inhibitor
NLRP3 mechanism: Unknown; not studied
Food safety: GRAS; used in cosmetics and food preservation
Status: Natural A. oryzae product; no engineering needed
Ergothioneine (2-(2-amino-3-sulfanylpropyl)-4-methyl-1,4-thiazolium)
Rare amino acid; potent antioxidant and ROS scavenger
NLRP3 mechanism: Likely indirect via ROS reduction (not directly tested)
Production: A. oryzae engineered for 20 mg/g dry weight (~100–500 mg/L fermentation) via EGT1/EGT2 heterologous expression and methionine supplementation
Food safety: GRAS; present in mushrooms, truffles
Potential: May synergize with polyphenols for ROS suppression; weak NLRP3 specificity
Ferulic acid (3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid)
Phenylpropanoid; antioxidant; precursor for vanillin
NLRP3 mechanism: Suppresses NLRP3 inflammasome via autophagy induction and blocking caspase-1 activation
Native presence: Koji produces ferulic acid during mold fermentation; can be further enhanced via ferruloyl esterase overexpression
Food safety: GRAS
Status: Likely already present in engineered koji fermentation; synergistic with other polyphenols
Isocoumarin derivatives, gliotoxin, aspergillic acid
Multiple secondary metabolites with antimicrobial and anticancer activities
NLRP3 mechanism: NOT studied; likely not NLRP3-selective

Conclusion on native A. oryzae: Koji naturally produces ergothioneine and ferulic acid; enhancing these via genetic engineering (overexpression of biosynthetic genes) could boost NLRP3 suppression without introducing non-native compounds. However, none of the native A. oryzae metabolites have been directly tested for NLRP3 inhibition.

Ranking: Top 5 Candidates by Evidence × Feasibility × Safety¶

Rank 1: Ursolic Acid (Triterpene)¶

Criterion	Score	Justification
NLRP3 evidence	8/10	Animal models (Kawasaki disease, vasculitis); mechanism clear (NF-κB, NLRP3, caspase-1); NOT gout-tested but extrapolates from OA models
Production feasibility	10/10	8.59 g/L bioreactor titer (2024 record); established MVA + triterpene synthase pathway; S. cerevisiae GRAS host
Food safety	10/10	GRAS status; present in apples, rosemary, oregano; safe up to 100–200 mg/day
Bioavailability	6/10	Poor water solubility; requires lipid formulation; stable triterpene resists GI degradation
Gout-specificity	5/10	NO direct gout evidence; inferred from OA models
Overall Score	39/50	Highest production titer + strong mechanism; extrapolation to gout reasonable

Recommendation: PRIMARY PRODUCTION CANDIDATE. Co-engineer into S. cerevisiae uricase strain alongside quercetin. Ursolic acid tier can sustain 100–200 mg/dose fermented beverage.

Rank 2: Quercetin (Flavonoid)¶

Criterion	Score	Justification
NLRP3 evidence	8/10	Gout-specific animal model (MSU-induced arthritis); 200–400 mg/kg reduces joint swelling, IL-1β, TNF-α; IC50 ~11 μM; NOT human RCT
Production feasibility	9/10	20.38 ± 2.57 mg/L in engineered S. cerevisiae; established PAL/CHS/CHI/F3H pathway; proven scalability
Food safety	10/10	GRAS; ubiquitous in plant foods; safe up to 1 g/day
Bioavailability	5/10	Poor (aglycone form); glycosidic formulations improve absorption; low bioavailability limits clinical effect
Gout-specificity	9/10	Direct gout animal evidence; suppresses IL-1β in MSU models
Overall Score	41/50	Best gout evidence + established production; adequate titers

Recommendation: PRIMARY NLRP3 INHIBITOR CANDIDATE for gout. Synergize with uricase in same S. cerevisiae construct. Quercetin production (20 mg/L) achieves therapeutic dosing in fermented beverage (500 mL @ 20 mg/L = 10 mg quercetin per dose; target ~50 mg/dose via fermenter optimization or co-fermentation).

Rank 3: Carnosine (Dipeptide)¶

Criterion	Score	Justification
NLRP3 evidence	9/10	Direct hyperuricemia rat evidence: Carnosine reduces serum uric acid AND inhibits inflammation; suppresses NLRP3, caspase-1, p-p65, p-JNK, URAT1, GLUT9
Production feasibility	6/10	Requires β-alanine + histidine + carnosine synthase; NOT extensively published for yeast; estimated 100–300 mg/L based on dipeptide analogs
Food safety	10/10	GRAS; meat-derived amino acid; safe up to 2 g/day
Bioavailability	10/10	Excellent; dipeptide transporters ensure intact absorption
Gout-specificity	10/10	Only candidate with direct hyperuricemia + NLRP3 linkage in rats
Overall Score	45/50	Highest gout relevance + excellent bioavailability; moderate production complexity

Recommendation: SECONDARY SYNERGY CANDIDATE. Carnosine's direct hyperuricemia evidence and dual mechanism (NLRP3 + urate excretion via URAT1/GLUT9) make it a strong co-engineer with uricase. Production feasibility moderate; recommend pilot fermentation before scale-up.

Rank 4: Taurine (Amino Acid)¶

Criterion	Score	Justification
NLRP3 evidence	8/10	Strong in sepsis and cardiac models; K+ efflux block upstream of ASC; well-characterized mechanism; NOT gout-tested
Production feasibility	7/10	Requires cysteinyl-CoA synthetase + cysteate sulfinyltransferase; feasible but titers not published; simple small molecule (expected high titers)
Food safety	10/10	GRAS; essential amino acid; safe up to 3 g/day
Bioavailability	10/10	Excellent; actively transported amino acid
Gout-specificity	4/10	NO gout evidence; mechanism inference only; may synergize with uricase (reduces renal urate reabsorption via SIRT1?)
Overall Score	39/50	Excellent safety + bioavailability; weak gout evidence

Recommendation: TERTIARY SYNERGY AGENT. Include in formulation for broad anti-inflammatory benefit + potential NLRP3 upstream block. Low production cost; pairs well with uricase + quercetin + carnosine.

Rank 5: Resveratrol (Stilbenoid)¶

Criterion	Score	Justification
NLRP3 evidence	7/10	Multiple animal models (arthritis, infection, IR injury); ROS/SIRT1 mechanisms clear; NOT gout-specific
Production feasibility	10/10	800 mg/L bioreactor titer (2020 record); proven PAL/STS pathway
Food safety	10/10	GRAS; wine polyphenol; decades of dietary supplement use
Bioavailability	4/10	Poor (~3 mg/L solubility); requires lipid formulation; <5% oral absorption
Gout-specificity	3/10	NO direct gout evidence; inferred from rheumatoid arthritis
Overall Score	34/50	Highest polyphenol titer; weak gout specificity + bioavailability challenge

Recommendation: SECONDARY OPTION if ursolic acid production proves limiting. Excellent production titer (800 mg/L); weak gout evidence limits prioritization vs. quercetin or carnosine. Better suited as antioxidant synergy partner in formulation.

Candidates NOT Recommended (Below Threshold)¶

Excluded Tier 3–4 Compounds¶

Compound	Reason for Exclusion
EGCG (engineered-production only)	Production titers 10–50 mg/L, complex 8–10 gene pathway. Note (2026-04-23): EGCG itself is promoted to Tier 2 for supplement use — direct MSU mouse gout evidence (Lee 2019 PMID 31174271) contradicts the prior "no gout evidence" rationale. Engineered path remains excluded on titer + pathway complexity grounds.
Curcumin	Severe bioavailability crisis (~5% oral absorption); requires nanoparticle/liposome formulation; high engineering cost for modest benefit
β-Caryophyllene (engineered-production only)	Very low titers (~10–50 mg/L); volatility issues; oral bioavailability poor. Supplement tier 2–3 given MSU gout rat model (Front Pharmacol 2021, PMID 33967792) — see entry.
Limonene (engineered-production only)	Extremely low titers (<20 mg/L); volatile; no oral bioavailability without inhalation. Supplement path promoted to Tier 3 (Venkatesan 2025 PMID 41515190).
Sulforaphane (engineered-production only)	Isothiocyanate; glucosinolate pathway never reconstructed in yeast. Supplement path promoted to Tier 2–3 (Wang 2022 hyperuricemic rat PMID 36371056; Nrf2 EC50 580 nM).
Omega-3 metabolites (resolvins, lipoxins, DHA)	Fatty acid derivatives; no published engineered microbial production; would require lipase + additional enzymatic coupling; complex fermentation; weak NLRP3-specific evidence

Integrated Production Strategy: "Koji-Yeast Hybrid"¶

Based on this screen, a synergistic engineered system combining S. cerevisiae and A. oryzae is recommended:

S. cerevisiae Uricase Strain Augmentation:¶

Primary load: Uricase (Tf-uricase or variant) for uric acid degradation
Secondary load: Ursolic acid biosynthesis (MVA pathway optimization + CYP/OSC/CPR triterpene synthase genes)
Tertiary load: Quercetin biosynthesis (PAL/CHS/CHI/F3H genes)

Expected output: 50–100 mg/L ursolic acid + 20 mg/L quercetin in fermented beverage; uricase activity intact

A. oryzae Koji Enhancement:¶

Natural baseline: Koji already produces ergothioneine (20 mg/g dry weight with optimization) and ferulic acid
Augmentation: Carnosine synthase heterologous expression from Lactobacillus
Benefit: Enhanced ergothioneine (ROS suppression) + natural ferulic acid (NLRP3 block) + engineered carnosine (hyperuricemia reversal)

Expected output: Multi-component koji with synergistic NLRP3 + urate regulation

IC50 Potency Gap: Scaling for Clinical Efficacy¶

Critical caveat: Benchmark NLRP3 inhibitors are 100–10,000× more potent than food-derived candidates: - MCC950: IC50 ~7.5 nM - Oridonin: Covalent Cys279 binder (irreversible inhibition) - Quercetin: IC50 ~11 μM (1,466× weaker) - Ursolic acid: IC50 not quantified; structural estimates suggest 5–50 μM range

Clinical strategy to overcome potency gap: 1. Dose escalation: Fermented beverage @ 50–100 mg/L ursolic acid + 20 mg/L quercetin = ~1–2 g/day intake (deliverable in 500 mL) 2. Synergy: Combine polyphenol + triterpene + carnosine + taurine for multi-target NLRP3 suppression 3. Barrier optimization: Co-administer with [[blood-barrier-exploits]] strategies (zonula occludens-1 enhancers, tight junction peptides) to maximize intestinal bioavailability 4. Temporal dosing: Administer 1–2 hours before uricase dosing to prime NLRP3 suppression; sustain IL-1β reduction for uric acid clearance

Summary Table: Candidates Ranked by Multi-Factor Score¶

Two-column IC50 discipline (updated 2026-04-23): The prior single-column "NLRP3 evidence" conflated two fundamentally different measurements. Cleanly separated below:

Direct NLRP3 IC50 (ChEMBL, human-cell) — curated binding/inhibition against human NLRP3 (CHEMBL1741208) in THP-1 / MDM / PBMC. The rigorous "does this compound inhibit NLRP3" column.
Functional IL-1β IC50 (MSU-stimulated) — IL-1β reduction in macrophage assays, pathway-modulator readouts. The "does this compound suppress the gout-relevant output" column.

The two measure different things and should not be cross-compared. Cell-free / mouse-cell figures are footnoted, not mixed into the human-cell column.

Rank	Compound	Direct NLRP3 IC50 (human-cell, ChEMBL)	Functional IL-1β IC50 (MSU)	Production (mg/L)	Gout-Specific	Bioavailability	Status
1	Ursolic Acid	— (no curated entry)	~μM range (estimated)	8590	NO (OA infer)	6/10	PRIMARY
2	Quercetin	— (no curated entry; most potent activity is 5-LOX 300 nM)	~11 μM (MSU macrophages)	20	YES (MSU rat)	5/10	PRIMARY
3	Carnosine	— (no curated entry)	μM range (LPS/HUA models)	150*	YES (HUA rat)	10/10	SECONDARY
3a	Lactoferrin	— (no direct NLRP3 IC50; CP5 downstream)	~μg/mL range (NLRP3/caspase-1/GSDMD axis)	3500 (P. pastoris)	NO (CP5 class)	8/10	TIER 1 CP5
4	Taurine	— (upstream K⁺ efflux, not direct)	μM–mM range	HIGH*	NO	10/10	TERTIARY
5	Resveratrol	— (no curated entry)	0.1–25 μM	800	NO	4/10	BACKUP
—	EGCG	— (no curated entry)	10–50 μM	30	YES (MSU mouse, Lee 2019)	5/10	SUPPLEMENT T2
—	Curcumin	24.2 μM (human THP-1, ChEMBL)	10–50 μM	100	YES (MSU)	1/10	NOT RECOMMENDED (bioavail)
—	β-Caryophyllene	— (docking only, no IC50)	μM range	20	YES (MSU rat)	2/10	SUPPLEMENT T2-3
—	Sulforaphane	— (no direct; Nrf2 EC50 580 nM)	μM range	— (no yeast path)	YES (HUA rat, Wang 2022)	6/10	SUPPLEMENT T2-3
—	Limonene	— (no curated entry)	μM range	20	YES (MSU rat, Venkatesan 2025)	2/10	SUPPLEMENT T3
Benchmark	Dapansutrile	1,000 nM (human MDM) ¹	—	synthetic	Phase 2a (PMID 33005902)	oral	PHARMA
Benchmark	Oridonin	5,180 nM (human THP-1) ²	—	extract	YES (MSU mouse, cell-free)	low	SUPPLEMENT

Estimated; not published ¹ ChEMBL CHEMBL3989943, Eur J Med Chem 2023. Mouse J774A.1 IC50 = 1 nM — 1,000× species gap, footnoted only. ² ChEMBL CHEMBL1164920, Eur J Med Chem* 2023. Cell-free covalent-binding kinetics of 0.5–2 μM (Nature Commun 2018) is a different measurement class and should not be cross-compared.

Recommendations for Next Steps¶

Phase 1: Validation (3–4 weeks)¶

Keratinocyte co-culture assay: Test quercetin + ursolic acid synergy on MSU-stimulated IL-1β secretion
Hyperuricemia rat model: Repeat carnosine + uricase co-dosing (compare to uricase alone)
Bioavailability study: Oral dosing of quercetin + ursolic acid in mice; measure serum levels at 1, 4, 24 h

Phase 2: Engineered Strain Construction (6–8 weeks)¶

S. cerevisiae: Engineer ursolic acid + quercetin biosynthesis in uricase-expressing strain
A. oryzae: Overexpress carnosine synthase in koji strain; verify ergothioneine + ferulic acid levels
Co-fermentation: Optimize fed-batch conditions for multi-compound production

Phase 3: Gout Efficacy (Pending regulatory guidance)¶

MSU-induced acute gout model: Test engineered yeast fermentation supernatant (quercetin + ursolic acid) vs. vehicle control
Dose-response: Establish minimal effective dose; compare to quercetin or ursolic acid alone
Mechanism validation: Measure ex vivo NLRP3 inflammasome activation in patient PBMCs after fermentation dosing

Conclusion¶

Ursolic acid and quercetin emerge as the primary candidates for engineered microbial production, offering the best balance of: - Established biosynthetic feasibility (ursolic acid: 8.59 g/L record titer) - NLRP3 inflammasome inhibition mechanism (both animal-model proven) - Food-safety profile (GRAS status)

Carnosine is recommended as a synergy partner due to its unique direct hyperuricemia evidence and excellent bioavailability, despite production complexity.

Taurine and resveratrol are suitable secondary agents for multi-target anti-inflammatory benefit, though neither has gout-specific evidence.

Integration into engineered S. cerevisiae + A. oryzae dual-organism systems would deliver a food-grade, synergistic NLRP3 inhibitor platform for Phase 2 gout efficacy testing, potentially positioned as a fermented functional food rather than pharmaceutical.

Appendix: ChEMBL IC50 Cross-Check (2026-04-23)¶

This section cross-references the IC50 values cited throughout this screen against the EMBL-EBI ChEMBL v34 curated bioactivity database (queried via the Anthropic life-sciences MCP). Purpose: separate "direct NLRP3 inhibition" claims (measurable in a binding/inhibition assay) from "NLRP3 pathway modulation" claims (inferred from downstream IL-1β readouts, NF-κB suppression, ROS scavenging, or mechanistic review).

NLRP3 target ID: CHEMBL1741208 (NACHT, LRR and PYD domains-containing protein 3, Homo sapiens, UniProt Q96P20).

What ChEMBL confirms with direct human NLRP3 bioactivity¶

Compound	ChEMBL ID	Human NLRP3 IC50 (direct)	Source (journal/year)
Dapansutrile (OLT1177)	CHEMBL3989943	1,000 nM (1.0 μM) — human MDM cells, LPS+nigericin, pChEMBL=6.00	Eur J Med Chem 2023
Oridonin	CHEMBL1164920	5,180 nM (5.18 μM) — human THP-1, LPS/ATP, pChEMBL=5.29	Eur J Med Chem 2023

That's it. Those are the only two compounds in the inhibitor screen with a curated, cited IC50 against human NLRP3 in ChEMBL.

Dapansutrile species gap (big surprise): ChEMBL shows dapansutrile at 1 nM (pChEMBL=9.00) in mouse J774A.1 cells (Eur J Med Chem 2020 and Bioorg Med Chem Lett 2021) — a 1,000× potency gap versus human cells. The wiki's reference to dapansutrile potency should note this interspecies difference: mouse preclinical assays make it look MCC950-class; human cell data puts it at the μM range. This reframes the 2020 Phase 2a clinical efficacy (52–84% pain reduction at 100–2000 mg/day) as consistent with human-cell μM potency at high oral doses, not sub-nM potency.

Oridonin: our wiki's "0.5–2 μM" claim is not supported by ChEMBL's curated human NLRP3 assay. The only ChEMBL entry is 5.18 μM in human THP-1 (2023). The 0.5–2 μM figure likely comes from cell-free or mouse-derived assays in the original Nature Communications 2018 paper (covalent Cys279 binding kinetics); it may not translate to cellular human IC50. Update the wiki framing accordingly.

What ChEMBL does NOT support with direct human NLRP3 data¶

Zero bioactivities found against CHEMBL1741208 (human NLRP3) for:

Quercetin (CHEMBL50) — 2,930 total bioactivities across other targets, zero against human NLRP3. The "IC50 ~11 μM" cited here is from functional IL-1β readouts in review literature, not a curated direct NLRP3 inhibition assay. Quercetin's most potent ChEMBL activity is against 5-lipoxygenase (5-LOX): IC50 = 300 nM (J Med Chem 1991) — a leukotriene-pathway target not currently represented in the NLRP3 Exploit Map. Worth adding to the wiki.
Ursolic acid (CHEMBL169) — zero direct human NLRP3 entries
Tranilast (CHEMBL415324) — zero direct human NLRP3 entries (despite the 2017 EMBO Mol Med paper claiming direct NACHT domain binding)
Beta-caryophyllene (CHEMBL445740) — zero direct human NLRP3 entries (the 2021 Front Pharmacol MSU gout paper used docking + downstream markers, not a direct NLRP3 inhibition IC50)

This is not a contradiction of the inhibitor screen's rankings. Functional IL-1β suppression in MSU-stimulated macrophages IS clinically relevant — it's what Open Enzyme actually cares about. But it IS a rigor upgrade to how we frame mechanisms: most "NLRP3 inhibitors" in the screen are more accurately NLRP3 pathway modulators that act upstream (NF-κB priming block, ROS reduction, K+ efflux prevention) or at unknown direct binding sites that haven't been characterized in the medicinal chemistry literature.

Implications¶

Two-tier labeling going forward: Distinguish "direct NLRP3 inhibitor (binding/inhibition IC50 measured)" from "NLRP3 pathway modulator (functional IL-1β reduction, mechanism inferred)." Only dapansutrile, oridonin, MCC950, and tranilast (per separate literature) have standing as direct NLRP3 inhibitors.
Quercetin 5-LOX angle is a missed opportunity. 5-LOX produces leukotrienes (LTB4) that drive neutrophil chemotaxis in gout flares. Quercetin's IC50 = 300 nM on 5-LOX is stronger than anything else in its pharmacology profile, and LTB4 is a known amplifier of MSU-driven inflammation. Worth adding as a quercetin-specific mechanism in the exploit map — complements the NF-κB story.
Dapansutrile's mouse-vs-human species gap (1000×) matters for translational claims. Several NLRP3 compounds show strong mouse activity that doesn't translate to human cells. This supports Open Enzyme's emphasis on human-cell (THP-1) validation assays over rodent models for NLRP3 screening.
MCC950 not retrievable by common synonyms (MCC950, CRID3, CP-456773) in ChEMBL's name search. The IC50 value cited in this screen (7.5 nM) comes from Coll et al. 2015 J Biol Chem and is widely cited but not directly verified by the MCP cross-check here. Known target: NACHT domain Walker B motif; benchmark status unchanged, just note the ChEMBL lookup remains open.

How to refresh¶

target_search(gene_symbol="NLRP3", organism="Homo sapiens")   # get CHEMBL1741208
compound_search(name="<compound>")                             # get molecule_chembl_id
get_bioactivity(molecule_chembl_id=<ID>, target_chembl_id="CHEMBL1741208", activity_type="IC50")

Refresh cadence: annually, or whenever a new direct NLRP3 inhibitor clinical program publishes pivotal data.

Sources¶

Polyphenol NLRP3 Inhibition¶

Terpenoid NLRP3 Mechanisms¶

SCFA Context-Dependent NLRP3¶

Amino Acid NLRP3 Inhibitors¶

Engineered Microbial Production¶

Dapansutrile Gout Clinical Trial¶

Phase 2a dapansutrile gout trial (PMC)

Koji Postbiotics & Metabolites¶

Gout-Specific NLRP3 & Uricase¶

[Open Enzyme internal docs: gout-deep-dive.md, nlrp3-exploit-map.md]
[ALLN-346 oral uricase Phase 2a (Project Milestone)]
[Rasburicase FDA approval 2001 (S. cerevisiae uricase background)]
Georgia State CRISPR S. cerevisiae uricase (2025)

Document prepared: 2026-04-21
Review status: Ready for validation phase planning
Next owner: Role 1 collaborator (enzymatic mechanism / in-vivo validation)